Disease Archives - Page 2 of 5 - Precision Medicine Group

Event: Endpoints 11, 2023

Morgan Labbree2023-08-28T15:25:37-04:00Cell & Gene Therapy, Events, Thought Leadership|

Precision is honored to be a sponsor of this year’s Endpoints 11 taking place on September 20, 2023, in Boston, MA. Join a select group of industry leaders for this year’s awards gala as we gather at the State Room in Downtown Boston for an evening of dinner, drinks and networking to meet the future of biotech.

Connect with our Advanced Therapy experts!

Date: Wednesday, September 20, 2023
Time: 5:30pm – 10:30 pm ET
Location: State Room, Boston, MA

CLICK HERE to reserve your spot.

(more…)

Conference: 4th Annual Gene Therapy Immunogenicity Summit

Morgan Labbree2023-08-24T13:33:14-04:00Cell & Gene Therapy, Events, Thought Leadership|

Precision will be at this year’s 4th Annual Gene Therapy Immunogenicity Summit, September 5 – 7, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the development for cell and gene therapies.

Connect with our Advanced Therapy experts!

Schedule a meeting with one our our experts
Stop by Precision’s booth
Be sure to attend Precision’s own, Travis Harrison’s presentation on September 6th, 2023, at 9:30 AM EDT

You can register for the 4th Annual Gene Therapy Immunogenicity Summit below:

REGISTER HERE

(more…)

White Paper: Cell and Gene Therapies: How High Can Prices Go?

Morgan Labbree2023-08-11T13:10:02-04:00Cell & Gene Therapy, News, Thought Leadership|

The concept of optimizing CGT value propositions begs the question of what is reasonable when it comes to breakthrough science and unprecedented therapeutic solutions. Can a $5 million price tag be justified? What about $10 million?

This white paper is based on a webinar convened by PRECISIONadvisors, focusing on cell and gene therapy (CGT) pricing. The webinar featured two in-house experts from the PRECISIONadvisors Global Pricing & Market Access practice: Richard Macaulay, Senior Vice President and David Carr, Senior Director.

(more…)

Conference: CAR-TCR Summit, 2023

Morgan Labbree2023-07-31T15:37:47-04:00Cell & Gene Therapy, Events, Thought Leadership|

Precision will be at this year’s CAR-TCR Summit August 29 – September 1, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization of cell therapies.

Speaking Engagements
Detailed descriptions for each speaking engagement are included below.

Precision ADVANCE will hold a welcome reception on August 29, 2023, at 5:30 pm.
Project Farma will be facilitating a Manufacturing track panel discussion “Keys to Success for a Commercial – Ready Cell Therapy Facility” on August 30, 2023, 4:30 – 5:00 pm.
Precision ADVANCE will be facilitating an Early-Stage Clinical Strategy track panel discussion “Strategies for Successful Clinical Development of Cell Therapies” on August 30, 2023, 4:30 – 5:00 pm.
Precision ADVANCE will have a plenary speaking position “The Journey of Commercializing Cell Therapies” on August 31, 2023, 8:05 – 8:50 am.

Connect with our Advanced Therapy experts

Visit us at booth 90 in the exhibition area
Schedule in-person or virtual meetings with one of our experts
Attend our ADVANCE-sponsored Welcome Reception on August 29, 2023, at 5:30 PM ET

(more…)

White Paper: mRNA Innovation Is Revolutionizing Disease Prevention

Morgan Labbree2023-11-09T08:12:07-05:00Cell & Gene Therapy, News, Thought Leadership|

The first FDA approved mRNA product was decades in the making, following many iterations throughout history the first mRNA vaccine in the US was brought to life. This achievement delivered aid to patients and healthcare providers during the most critical public health crisis in recent years. Since then, researchers have been operating at incredible speeds to develop more novel mRNA treatment options for patients, across many indications.

In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and Chad Salisbury, Senior Vice President of Project Farma (PF), discuss the mRNA revolution and its impact on the future of disease prevention and treatment.

(more…)

White Paper: Moving Clinical Development Forward in 2023

Morgan Labbree2023-07-24T21:05:36-04:00Cell & Gene Therapy, News, Thought Leadership|

In today’s cell and gene therapy landscape, there are over 1,400 companies striving to move their products forward into clinic—a critical step in commercializing these groundbreaking treatments. Clinical development is a complex endeavor and the path to market requires careful consideration of factors ranging from chemistry, manufacturing, and controls (CMC) and regulatory strategy to study design, CRO selection, and clinical trial diversity.

(more…)

White Paper: The Price is Right: Cell and Gene Therapy Approvals and Market Access in 2023

Morgan Labbree2023-07-24T21:06:01-04:00Cell & Gene Therapy, News, Thought Leadership|

Starting health economic evidence development and market access planning as early as possible in clinical development for a cell and gene therapy is important demonstrating the value to payers and health technology appraisal (HTA) organizations. In a dynamic regulatory and market access landscape, balancing the requirements of regulators and the expectations of payors can be challenging since there is no one-size-fits-all approach.

(more…)

White Paper: The Future is Now: Cell and Gene Therapy Innovation, Challenges, and Perspectives

Morgan Labbree2023-07-24T21:06:29-04:00Cell & Gene Therapy, News, Thought Leadership|

Cell and gene therapies have the potential to revolutionize treatment of a wide range of diseases. With six new therapies approved in 2022, including the first allogeneic T-cell therapy, and at least as many slated for approval this year, the sector is poised for rapid growth. This innovation comes with challenges, though, and many consider 2023 to be a seminal year for establishing a strong foothold for advanced therapies in mainstream medicine.

(more…)

Executive Summary: State of the Industry

Morgan Labbree2023-07-24T21:06:57-04:00Cell & Gene Therapy, News, Thought Leadership|

Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), kicked off the event with a briefing on the state of the cell and gene therapy development landscape. With 475 members worldwide, ARM focuses on convening the sector, providing data and analysis, engaging with stakeholders, and enabling the development of advanced therapies. One of their key initiatives is modernizing healthcare systems to enable access to these novel therapeutics. Highlights of this briefing are provided in this summary.

(more…)

White Paper: Gene Editing Breakthroughs: A New Hope for Patients

Morgan Labbree2023-06-20T14:19:37-04:00Cell & Gene Therapy, News, Thought Leadership|

Gene editing technology has rapidly evolved over the past decade. From the initial breakthrough of sequencing the first human genome to researchers today having the ability to create genetically modified mice in as little as four weeks. CRISPR Cas-based gene editing, which acts as a pair of genomic scissors, is at the core of these innovations. The revolutionary technology has enabled rapid genome sequencing and editing to spur advancements in disease research and treatment.

In this white paper, Anshul Mangal President of Project Farma and Precision ADVANCE and Cynthia Pussinen, Advisor & Executive Consulting Partner share how the latest breakthroughs in gene editing technology have the potential to dramatically improve outcomes for patients.

(more…)